Background alzheimers Shape Background alzheimers Shape Background alzheimers Shape
Grants > Amyloid Assembly and Cerebral Endothelial Cells Response Updated On: Jan. 19, 2025
Alzheimer's Disease Research Grant

Amyloid Assembly and Cerebral Endothelial Cells Response

BFF logo

Principal Investigator

Agueda Rostagno, PhD

New York University Grossman School of Medicine

New York, NY, USA

About the Research Project

Program

Alzheimer's Disease Research

Award Type

Standard

Award Amount

$299,959

Active Dates

April 01, 2004 - March 31, 2007

Grant ID

A2004017

Summary

Cerebral Amyloid Angiopathy (CAA) is the generic name for a large group of diseases characterized by the presence of amyloid beta fibrils (Aß) in small vessels and medium-sized arteries and arterioles in the brain. Although Aß is the most common CAA amyloid, many other proteins have been associated with the formation of amyloid deposits in the brain. Some of these proteins are cystatin C, transthyretin, gelsolin, and the recently described ABri and ADan peptides. The ABri and ADan peptides are associated with two rare hereditary conditions—familial British and Danish dementias—that are characterized by extensive CAA and Alzheimer’s-like neurodegeneration. This is an indication that different amyloid molecules may lead to the same scenario of neuronal loss and dementia. Dr. Rostagno’s is working with fibrils and pre-fibrils of various amyloid molecules and the hereditary variants involved in the production of CAA in cultures. These compounds will be fed to human cerebral endothelial cells in culture, and their toxicity as well as their ability to induce inflammation will be assessed by biochemical analysis. It is hoped that an understanding of the molecular events triggered by the toxic peptides will lead to the design and development of new treatments to modulate these cellular processes and ameliorate the impact of these neurological diseases.